Shine Investment Advisory Services Inc. increased its position in Pfizer Inc. (NYSE:PFE) by 157.6% in the third quarter, Holdings Channel reports. The fund owned 7,817 shares of the biopharmaceutical company’s stock after purchasing an additional 4,783 shares during the period. Shine Investment Advisory Services Inc.’s holdings in Pfizer were worth $279,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. American National Bank grew its position in Pfizer by 0.6% in the 2nd quarter. American National Bank now owns 155,031 shares of the biopharmaceutical company’s stock worth $5,207,000 after purchasing an additional 982 shares during the period. Catawba Capital Management VA grew its position in Pfizer by 3.4% in the 2nd quarter. Catawba Capital Management VA now owns 203,040 shares of the biopharmaceutical company’s stock worth $6,820,000 after purchasing an additional 6,635 shares during the period. Curbstone Financial Management Corp grew its position in Pfizer by 2.1% in the 2nd quarter. Curbstone Financial Management Corp now owns 28,005 shares of the biopharmaceutical company’s stock worth $941,000 after purchasing an additional 583 shares during the period. Stillwater Capital Advisors LLC grew its position in Pfizer by 1.6% in the 2nd quarter. Stillwater Capital Advisors LLC now owns 372,131 shares of the biopharmaceutical company’s stock worth $12,500,000 after purchasing an additional 5,876 shares during the period. Finally, Beacon Financial Group grew its position in Pfizer by 2.3% in the 2nd quarter. Beacon Financial Group now owns 228,070 shares of the biopharmaceutical company’s stock worth $7,670,000 after purchasing an additional 5,027 shares during the period. Institutional investors own 69.75% of the company’s stock.

A number of research firms have commented on PFE. Vetr downgraded shares of Pfizer from a “buy” rating to a “hold” rating and set a $37.98 target price for the company. in a research report on Monday. BMO Capital Markets set a $39.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research report on Monday, January 8th. Morgan Stanley set a $41.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research report on Friday, January 5th. Nord/LB reaffirmed a “neutral” rating on shares of Pfizer in a research report on Tuesday, January 2nd. Finally, UBS Group set a $40.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research report on Wednesday, December 6th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $38.83.

Shares of Pfizer Inc. (PFE) opened at $36.54 on Monday. Pfizer Inc. has a 1 year low of $30.90 and a 1 year high of $37.35. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43. The stock has a market cap of $217,804.23, a price-to-earnings ratio of 14.62, a PEG ratio of 2.44 and a beta of 1.01.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The firm had revenue of $13.17 billion during the quarter, compared to the consensus estimate of $13.17 billion. During the same quarter in the previous year, the firm posted $0.61 EPS. The company’s revenue for the quarter was up .9% compared to the same quarter last year. sell-side analysts forecast that Pfizer Inc. will post 2.59 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be given a dividend of $0.34 per share. This is an increase from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date of this dividend is Thursday, February 1st. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.72%. Pfizer’s payout ratio is presently 79.01%.

Pfizer declared that its Board of Directors has authorized a stock repurchase program on Monday, December 18th that permits the company to repurchase $10.00 billion in shares. This repurchase authorization permits the biopharmaceutical company to buy shares of its stock through open market purchases. Shares repurchase programs are generally a sign that the company’s board believes its stock is undervalued.

In related news, insider Alexander R. Mackenzie sold 6,750 shares of the company’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $37.00, for a total value of $249,750.00. Following the completion of the transaction, the insider now owns 103,458 shares of the company’s stock, valued at approximately $3,827,946. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Rady A. Johnson sold 8,000 shares of the company’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $37.07, for a total transaction of $296,560.00. Following the completion of the transaction, the executive vice president now directly owns 46,963 shares of the company’s stock, valued at approximately $1,740,918.41. The disclosure for this sale can be found here. In the last three months, insiders have sold 29,450 shares of company stock valued at $1,065,220. Insiders own 0.06% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.watchlistnews.com/pfizer-inc-pfe-position-boosted-by-shine-investment-advisory-services-inc/1807882.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.